Peeling Back The Layers: Exploring Pacira BioSciences Through Analyst Insights
Portfolio Pulse from Benzinga Insights
Analysts' ratings for Pacira BioSciences (NASDAQ:PCRX) show mixed sentiments, with recent ratings being predominantly bullish. The average 12-month price target has declined slightly to $47.17. Key analysts have maintained or lowered their ratings and price targets, reflecting their response to recent developments. Pacira BioSciences has shown notable revenue growth and strong net margins but faces challenges with ROE.
July 02, 2024 | 7:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Analysts' ratings for Pacira BioSciences (NASDAQ:PCRX) show mixed sentiments, with recent ratings being predominantly bullish. The average 12-month price target has declined slightly to $47.17. Key analysts have maintained or lowered their ratings and price targets, reflecting their response to recent developments.
The mixed analyst ratings and slight decline in the average price target suggest a neutral short-term impact on PCRX's stock price. While the majority of recent ratings are bullish, the overall sentiment is tempered by some analysts lowering their price targets.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100